Picture Demy-Colton BioFuture 2024 NYC 3 Biotech Breakthroughs 650x100px
Organisation › Details

Cardior Pharmaceuticals GmbH

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide. *


Period Start 2016-07-05 established (s-off)
  Group Novo Group (Group)
  Predecessor MHH (Hanover Medical School / Medizinische Hochschule Hannover)
Products Industry CDR132L (Cardior Pharmaceuticals)
  Industry 2 RNA-based therapeutic
Persons Person Ulbrich, Claudia (Cardior Therapeutics 201705– CEO before T-Cell Europe GmbH 201205 Managing Director)
  Person 2 Thum, Thomas (MHH 201607 Prof + Cardior Pharmaceuticals 201607 Managing Director + Founder)
Region Region Hannover (Hanover)
  Country Germany
  Street 15 Feodor-Lynen-Str.
  City 30625 Hannover
    Address record changed: 2024-03-26
Basic data Employees A: 1 to 10 (2018-12-20)
    * Document for »About Section«: Cardior Pharmaceuticals GmbH. (3/25/24). "Press Release: Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease". Bagsværd & Hannover.
Record changed: 2024-03-26


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Novo Group (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top